A Phase 4 interventional study of Insulin glulisine and Insulin lispro in Diabetes Mellitus, Type 1, sponsored by Sanofi. Completed at 12 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-08-31.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 1.
Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1, this one is the 3rd largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2008, is one of 14 in phase 4, and was the 11th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2008.
This study's enrollment of 289 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 72 across the 25 interventional studies. Of the 25 that completed or were terminated, 3 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 26 have an industry lead sponsor. The 8 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
67 studies in Diabetes Mellitus, Type 1 by Sanofi: 6 open now, 10 under way, 1 of them phase 3. Of 56 finished, 13 (23%) have results posted.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 15th largest by enrollment of the 60 interventional ones that give a count, is the only one that started in 2008, is one of 14 in phase 4, and was the 17th registered.
Sanofi’s Diabetes Mellitus, Type 1 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 67 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
Primary objective: To demonstrate the superiority of insulin glulisine over insulin aspart and insulin lispro administered by external pump in term of unexplained hyperglycemia and/or infusion set occlusion.
Main Secondary objectives:
To compare insulin glulisine, insulin aspart and insulin lispro on:
The maximal duration of the study participation for patients was 41 weeks and one day, split in:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
sequence 1: insulin glulisine / insulin aspart / insulin lispro.
Drug: Insulin glulisine · Drug: Insulin lispro · Drug: Insulin aspart
Sequence 2: insulin aspart / insulin lispro / insulin glulisine
Drug: Insulin glulisine · Drug: Insulin lispro · Drug: Insulin aspart
Sequence 3: insulin lispro / insulin glulisine / insulin aspart
Drug: Insulin glulisine · Drug: Insulin lispro · Drug: Insulin aspart
100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion
Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason. Pump infusion set occlusion defined by at least one of the following items: * pump occlusion alarm, * patient observation of an occlusion, spontaneously or because of elevated blood glucose value.
Time frame: over 13 weeks of each treatment period
Monthly Rate of Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion
Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason. Pump infusion set occlusion defined by at least one of the following items: * pump occlusion alarm, * patient observation of an occlusion, spontaneously or because of elevated blood glucose value.
Time frame: over 13 weeks of each treatment period
Percentage of Patients With at Least One Unexplained Hyperglycemia
Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason.
Time frame: over 13 weeks of each treatment period
Monthly Rate of Unexplained Hyperglycemia
Time frame: over 13 weeks of each treatment period
Percentage of Patients With at Least One Confirmed Infusion Set Occlusion
Pump infusion set occlusion defined by at least one of the following items: * pump occlusion alarm, * patient observation of an occlusion, spontaneously or because of elevated blood glucose value.
Time frame: over 13 weeks of each treatment period
Monthly Rate of Confirmed Infusion Set Occlusion
Time frame: over 13 weeks of each treatment period
Percentage of Patients With at Least One Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis
Diabetic ketoacidosis (DKA) is preceded by an increase in ketone production, resulting in blood ketone value increase (hyperketonemia) and later in ketone urine value (hyperketonuria). Significant hyperketonemia and risk level for impending diabetic ketoacidosis (DKA) are reported respectively as a blood ketone value from 0.6 to 1.5 mmol/L and \>1.5 mmol/l
Time frame: over 13 weeks of each treatment period
Monthly Rate of Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis
Diabetic ketoacidosis (DKA) is preceded by an increase in ketone production, resulting in blood ketone value increase (hyperketonemia) and later in ketone urine value (hyperketonuria). Significant hyperketonemia and risk level for impending diabetic ketoacidosis (DKA) are reported respectively as a blood ketone value from 0.6 to 1.5 mmol/L and \>1.5 mmol/l
Time frame: over 13 weeks of each treatment period
Rate of Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤ 70 mg/dL Per Patient-year
Symptomatic hypoglycemia is defined as an event with clinical symptoms that are considered to results from hypoglycemia (confirmed or not by a glucose measurement) and associated with prompt recovery after oral carbohydrate administration.
Time frame: over 13 weeks of each treatment period
Rate of Severe Symptomatic Hypoglycemia Per Patient-year
Severe symptomatic hypoglycemia is defined as an event with clinical symptoms that are considered to results from hypoglycemia in which the patient required assistance of another person and one of the following: * the event was associated with a measured blood glucose level below 36 mg/dL * or event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.
Time frame: over 13 weeks of each treatment period
Rate of Nocturnal Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤70 mg/dL Per Patient-year
Nocturnal Symptomatic hypoglycemia was defined as an event with clinical symptoms that are considered to result from hypoglycemia (confirmed or not by a glucose measurement) and associated with prompt recovery after oral carbohydrate administration which occurs while the patient is asleep, after bedtime and before getting up in the morning.
Time frame: over 13 weeks of each treatment period
Patients With at Least One Site Infection, Site Inflammation/Erythema, Pruritus or Isolated Pain at Injection Site
Infection: local reaction at the infusion site requiring local or systemic antibiotherapy, or local drainage as per Investigator judgment. Site inflammation or erythema: local reaction at the infusion site with no need for local or systemic antibiotherapy as per Investigator judgment. Pruritis at injection site: presence of pruritis at the infusion site without any symptom of inflammation or erythema and/or infection. Isolated pain at injection site: presence of pain at the infusion site without any symptom of inflammation or erythema and/or infection.
Time frame: over 13 weeks of each treatment period
Time Interval Between Infusion Set Changes: All Changes
Patients treated with insulin pump have to change their infusion set regularly (i.e.change was recommended every 48h). The patients were asked to report any change of their infusion set and the reason for change (routine basis or because of occurrence of a specific event such as occlusion, unexplained hyperglycemia or adverse event). "All changes" include all the changes whatever the reason such as routine or requested by occurrence of events.
Time frame: over 13 weeks of each treatment period
Time Interval Between Infusion Set Changes in Routine
Patients treated with insulin pump have to change their infusion set regularly (i.e.change was recommended every 48h). The patients were asked to report any change of their infusion set and the reason for change (routine basis or because of occurrence of a specific event such as occlusion, unexplained hyperglycemia or adverse event). Changes in routine correspond to interval between changes according to patient use.
Time frame: over 13 weeks of each treatment period
Glycosylated Hemoglobin: HbA1c
Glycolysated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow-up in diabetic patients. This parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c \<7%
Time frame: over 13 weeks of each treatment period
Total Daily Basal Insulin Infusion
dose of the basal insulin regimen administered throughout the 24-hour period
Time frame: over 13 weeks of each treatment period
Total Daily Bolus Insulin Dose
dose of every increment administered for example before meals
Time frame: over 13 weeks of each treatment period
Multicenter study: 44 active centers from 12 countries in Europe, USA and Asia Pacific region. Study Initiation date: January 8, 2008, Study Completion Date: June 15, 2009.
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 |
|---|---|---|---|
| Started | 99 | 95 | 94 |
| Completed | 84 | 84 | 84 |
| Not completed | 15 | 11 | 10 |
| Withdrew: Withdrawal by subject | 9 | 4 | 4 |
| Withdrew: Adverse event | 3 | 2 | 3 |
| Withdrew: Other reason | 1 | 5 | 2 |
| Withdrew: Poor compliance to protocol | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 |
|---|---|---|---|
| Started | 99 | 95 | 94 |
| Completed | 87 | 89 | 89 |
| Not completed | 12 | 6 | 5 |
| Withdrew: Withdrawal by subject | 7 | 2 | 3 |
| Withdrew: Adverse event | 3 | 0 | 0 |
| Withdrew: Poor compliance to protocol | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Other reason | 0 | 4 | 2 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 |
|---|---|---|---|
| Started | 87 | 89 | 89 |
| Completed | 86 | 86 | 84 |
| Not completed | 1 | 3 | 5 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Withdrew: Other reason | 1 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 3 |
| Withdrew: Poor compliance to protocol | 0 | 0 | 1 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 |
|---|---|---|---|
| Started | 86 | 86 | 84 |
| Completed | 84 | 84 | 84 |
| Not completed | 2 | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason. Pump infusion set occlusion defined by at least one of the following items: * pump occlusion alarm, * patient observation of an occlusion, spontaneously or because of elevated blood glucose value.
| percentage of patients | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion | 68.4 (62.7 to 74.1) | 62.1 (56.2 to 68.1) | 61.3 (55.4 to 67.3) |
Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason. Pump infusion set occlusion defined by at least one of the following items: * pump occlusion alarm, * patient observation of an occlusion, spontaneously or because of elevated blood glucose value.
| events per patient per month | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| Monthly Rate of Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion | 2.02 ± 0.15 | 1.32 ± 0.15 | 1.54 ± 0.15 |
Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason.
| percentage of patients | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| Percentage of Patients With at Least One Unexplained Hyperglycemia | 61.3 (55.4 to 67.3) | 55.9 (49.8 to 61.9) | 56.3 (50.2 to 62.3) |
| events per patient per month | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| Monthly Rate of Unexplained Hyperglycemia | 1.61 ± 0.13 | 1.04 ± 0.13 | 1.23 ± 0.13 |
Pump infusion set occlusion defined by at least one of the following items: * pump occlusion alarm, * patient observation of an occlusion, spontaneously or because of elevated blood glucose value.
| percentage of patients | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| Percentage of Patients With at Least One Confirmed Infusion Set Occlusion | 32.8 (27.1 to 38.6) | 27.0 (21.5 to 32.4) | 27.0 (21.5 to 32.4) |
| events per patient per month | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| Monthly Rate of Confirmed Infusion Set Occlusion | 0.41 ± 0.06 | 0.28 ± 0.06 | 0.31 ± 0.06 |
Diabetic ketoacidosis (DKA) is preceded by an increase in ketone production, resulting in blood ketone value increase (hyperketonemia) and later in ketone urine value (hyperketonuria). Significant hyperketonemia and risk level for impending diabetic ketoacidosis (DKA) are reported respectively as a blood ketone value from 0.6 to 1.5 mmol/L and \>1.5 mmol/l
| percentage of patients | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| Percentage of Patients With at Least One Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis | 17.6 (12.9 to 22.2) | 10.9 (7.1 to 14.8) | 11.7 (7.8 to 15.7) |
Diabetic ketoacidosis (DKA) is preceded by an increase in ketone production, resulting in blood ketone value increase (hyperketonemia) and later in ketone urine value (hyperketonuria). Significant hyperketonemia and risk level for impending diabetic ketoacidosis (DKA) are reported respectively as a blood ketone value from 0.6 to 1.5 mmol/L and \>1.5 mmol/l
| events per patient per month | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| Monthly Rate of Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis | 0.14 ± 0.43 | 0.06 ± 0.22 | 0.06 ± 0.18 |
Symptomatic hypoglycemia is defined as an event with clinical symptoms that are considered to results from hypoglycemia (confirmed or not by a glucose measurement) and associated with prompt recovery after oral carbohydrate administration.
| events in patient-year | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| Rate of Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤ 70 mg/dL Per Patient-year | 73.88 ± 4.74 | 65.06 ± 4.74 | 62.74 ± 4.74 |
Severe symptomatic hypoglycemia is defined as an event with clinical symptoms that are considered to results from hypoglycemia in which the patient required assistance of another person and one of the following: * the event was associated with a measured blood glucose level below 36 mg/dL * or event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.
| events in patient-year | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| Rate of Severe Symptomatic Hypoglycemia Per Patient-year | 1.63 ± 0.35 | 1.39 ± 0.35 | 1.07 ± 0.35 |
Nocturnal Symptomatic hypoglycemia was defined as an event with clinical symptoms that are considered to result from hypoglycemia (confirmed or not by a glucose measurement) and associated with prompt recovery after oral carbohydrate administration which occurs while the patient is asleep, after bedtime and before getting up in the morning.
| events in patient-year | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| Rate of Nocturnal Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤70 mg/dL Per Patient-year | 12.80 ± 0.95 | 9.66 ± 0.95 | 9.48 ± 0.95 |
Infection: local reaction at the infusion site requiring local or systemic antibiotherapy, or local drainage as per Investigator judgment. Site inflammation or erythema: local reaction at the infusion site with no need for local or systemic antibiotherapy as per Investigator judgment. Pruritis at injection site: presence of pruritis at the infusion site without any symptom of inflammation or erythema and/or infection. Isolated pain at injection site: presence of pain at the infusion site without any symptom of inflammation or erythema and/or infection.
| patients | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| Patients With at Least One Site Infection, Site Inflammation/Erythema, Pruritus or Isolated Pain at Injection Site | 110 | 110 | 107 |
Patients treated with insulin pump have to change their infusion set regularly (i.e.change was recommended every 48h). The patients were asked to report any change of their infusion set and the reason for change (routine basis or because of occurrence of a specific event such as occlusion, unexplained hyperglycemia or adverse event). "All changes" include all the changes whatever the reason such as routine or requested by occurrence of events.
| hours | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| Time Interval Between Infusion Set Changes: All Changes | 69.1 ± 20.70 | 69.44 ± 19.22 | 69.98 ± 21.64 |
Patients treated with insulin pump have to change their infusion set regularly (i.e.change was recommended every 48h). The patients were asked to report any change of their infusion set and the reason for change (routine basis or because of occurrence of a specific event such as occlusion, unexplained hyperglycemia or adverse event). Changes in routine correspond to interval between changes according to patient use.
| hours | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| Time Interval Between Infusion Set Changes in Routine | 70.72 ± 21.47 | 71.00 ± 20.68 | 71.07 ± 21.65 |
Glycolysated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow-up in diabetic patients. This parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c \<7%
| percentage | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| First week (week 1) (n=253, n=254, n=255) | 7.31 ± 0.71 | 7.33 ± 0.71 | 7.28 ± 0.71 |
| Last week (week 13) (n=252, n=255, n=251) | 7.32 ± 0.03 | 7.25 ± 0.03 | 7.33 ± 0.03 |
dose of the basal insulin regimen administered throughout the 24-hour period
| Units | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| First week (week 1) (n=251, n=249, n=250) | 20.83 ± 9.05 | 20.93 ± 9.45 | 20.85 ± 9.16 |
| Last week (week 13) (n=251, n=249, n=251) | 20.86 ± 9.24 | 20.81 ± 9.73 | 21.11 ± 9.38 |
dose of every increment administered for example before meals
| Units | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| First week (week 1) (n=249, n=247, n=250) | 18.63 ± 9.22 | 18.49 ± 9.00 | 18.40 ± 8.69 |
| Last week (week 13) (n=248, n=244, n=249) | 18.58 ± 8.49 | 18.64 ± 9.60 | 19.19 ± 9.13 |
Collected over Adverse events are collected from the first to the last drug intake (3 periods x 13 weeks) + 1 week after the administration of the last intake i.e. end of the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Glulisine | — | 29/274 (10.6%) | 47/274 (17.2%) |
| Insulin Aspart | — | 18/266 (6.8%) | 24/266 (9%) |
| Insulin Lispro | — | 11/269 (4.1%) | 30/269 (11.2%) |
| Event | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| ketosisMetabolism and nutrition disorders | 9/274 | 4/266 | 2/269 |
| hypoglycaemic seizureMetabolism and nutrition disorders | 8/274 | 3/266 | 4/269 |
| hypoglycaemic unconsciousnessMetabolism and nutrition disorders | 4/274 | 6/266 | 2/269 |
| hypoglycaemiaMetabolism and nutrition disorders | 3/274 | 0/266 | 0/269 |
| arteritis coronaryCardiac disorders | 0/274 | 1/266 | 0/269 |
| coronary artery stenosisCardiac disorders | 0/274 | 1/266 | 0/269 |
| myocardial infarctionCardiac disorders | 0/274 | 1/266 | 0/269 |
| overdoseInjury, poisoning and procedural complications | 1/274 | 1/266 | 0/269 |
| headacheNervous system disorders | 0/274 | 1/266 | 0/269 |
| hypoglycaemic comaNervous system disorders | 0/274 | 1/266 | 0/269 |
| Event | Insulin Glulisine | Insulin Aspart | Insulin Lispro |
|---|---|---|---|
| KetosisMetabolism and nutrition disorders | 47/274 | 24/266 | 30/269 |
| Age Continuous(years) | Sequence 1 | Sequence 2 | Sequence 3 | Total |
|---|---|---|---|---|
| Mean | 43.45 ± 13.71 | 45.84 ± 13.59 | 44.04 ± 12.87 | 44.43 ± 13.39 |
| Sex: Female, Male(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Total |
|---|---|---|---|---|
| Female | 49 | 54 | 48 | 151 |
| Male | 50 | 41 | 46 | 137 |
| Region of Enrollment(participants) | Sequence 1 | Sequence 2 | Sequence 3 | Total |
|---|---|---|---|---|
| United States | 22 | 21 | 21 | 64 |
| France | 8 | 9 | 10 | 27 |
| Hungary | 4 | 4 | 6 | 14 |
| Spain | 11 | 9 | 10 | 30 |
| Austria | 7 | 9 | 8 | 24 |
| Australia | 4 | 4 | 3 | 11 |
| Israel | 11 | 11 | 10 | 32 |
| Netherlands | 8 | 8 | 7 | 23 |
| United Kingdom | 5 | 4 | 4 | 13 |
| Italy | 9 | 7 | 7 | 23 |
| Sweden | 9 | 8 | 7 | 24 |
| Korea, Republic of | 1 | 1 | 1 | 3 |
| Previous insulin at study entry(participants) | Sequence 1 | Sequence 2 | Sequence 3 | Total |
|---|---|---|---|---|
| Insulin glulisine | 4 | 2 | 2 | 8 |
| Insulin aspart | 32 | 43 | 42 | 117 |
| Insulin lispro | 63 | 49 | 50 | 162 |
| Duration of treatment with previous insulin at study entry(years) | Sequence 1 | Sequence 2 | Sequence 3 | Total |
|---|---|---|---|---|
| Mean | 4.84 ± 3.58 | 4.37 ± 3.05 | 4.79 ± 3.00 | 4.67 ± 3.22 |
| Duration of treatment with insulin at study entry(years) | Sequence 1 | Sequence 2 | Sequence 3 | Total |
|---|---|---|---|---|
| Mean | 22.39 ± 13.53 | 23.07 ± 13.33 | 22.75 ± 11.08 | 22.73 ± 12.67 |
| Total daily bolus insulin dose(Units) | Sequence 1 | Sequence 2 | Sequence 3 | Total |
|---|---|---|---|---|
| Mean | 19.61 ± 9.40 | 18.58 ± 10.34 | 19.35 ± 7.78 | 19.18 ± 9.22 |
| Duration of treatment with CSII (continuous subcutaneous insulin infusion) at study entry(years) | Sequence 1 | Sequence 2 | Sequence 3 | Total |
|---|---|---|---|---|
| Mean | 5.99 ± 4.83 | 5.52 ± 5.27 | 6.31 ± 4.95 | 5.94 ± 5.01 |
4 further baseline measures are reported on the registry.
The record gives a start of Jan 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin glulisine · Insulin Lispro · Insulin Aspart